ClinicalTrials.gg
CompletedNCT03909971Updated Nov 5, 2025Results posted

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

A Phase 2 interventional study of Lorlatinib in Carcinoma, Non-Small-Cell Lung, sponsored by Pfizer. Completed at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-05.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 16 under way, 1 of them phase 3. lorlatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 27
109 · median 45
Started
2019
with 1 other
Phase 2
16 of 27
6 open now
Registered
8th of 27
by date
Lead sponsor
8 of 27
Pfizer

Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 2 that started in 2019, is one of 16 in phase 2, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About lorlatinib

lorlatinib: first FDA approval 2018 (LORBRENA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic ALK positive non small cell lung cancer patients in China

Read the detailed description

This is a Phase 2, China only, multi center, open label, dual cohort study, in ALK positive locally advanced or metastatic NSCLC patients will be enrolled to receive lorlatinib monotherapy.

  • (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor.
  • (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib.
03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • ALK positive
  • ALK inhibitor-treated
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Evidence of or cytologically confirmed diagnosis of locally advanced or ALK positive NSCLC where ALK status has been previously established by the Ventana ALK (D5F3) CDx Assay (Roche Diagnostics), the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular), or the EML4 ALK Fusion Gene Detection Kit (AmoyDx).
  2. Subject should have:

    1. (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor;
    2. (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib, with or without prior crizotinib.
  3. Prior treatment with an ALK inhibitor must have completed 5 half lives prior to study entry.
  4. All Subjects must have at least 1 measurable extracranial target lesion according to v1.1 that has not been previously irradiated. are allowed if:

    1. Asymptomatic: either not currently requiring treatment, or on a stable or decreasing dose of 10 mg QD prednisone or equivalent; or
    2. Previously diagnosed and treatment has been completed with full recovery from the acute effects of radiation therapy or surgery prior to enrollment, and if corticosteroid treatment for these metastases has been withdrawn for at least 4 weeks with neurological stability.
  5. performance status (ECOG PS) 0, 1, or 2.
  6. Age 18 years (or 20 years as required by local regulation).
  7. Adequate bone marrow functions:

    1. (ANC) 1,500/mm3 or 1.5 x 109/L;
    2. 100,000/mm3 or 100 x 109/L;
    3. 9 g/dL.
  8. Adequate pancreatic function:

    1. Serum total amylase 1.5 x (ULN);*
    2. Serum lipase 1.5 x ULN. *if total amylase >1.5 x ULN, but pancreatic amylase is within the ULN, then subject may be enrolled.
  9. Adequate renal function:

    a. Serum creatinine 1.5 x ULN or estimated 60 mL/min as calculated using the method standard for the institution.

  10. Adequate liver function:

    1. Total serum 1.5 x ULN;
    2. (AST) and Alanine Aminotransferase (ALT) 2.5 x ULN (5.0 x ULN in case of liver metastases).
  11. Acute effects of prior radiotherapy and chemotherapy resolved to baseline severity or to National Cancer Institute (NCI) (CTCAE) Grade 1 except for AEs that in the investigator's judgment do not constitute a safety risk for the subject.
  12. Serum or urine pregnancy test (for females of ) negative at screening. Female subjects of non childbearing potential must meet at least 1 of the following criteria:

    1. Achieved status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause (which may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state if appropriate;
    2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
    3. Have medically confirmed ovarian failure. All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.
  13. Evidence of a personally signed and dated document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
  14. Willing and able to comply with the study scheduled visits, treatment plans, laboratory tests, and other procedures.

Exclusion criteria

Exclusion Criteria:

Subjects with any of the following characteristics/conditions will not be included in the study:

  1. More than 1 prior chemotherapy regimen prior to enrollment in advanced/ setting.

    If disease recurred/ within the chemotherapy treatment or \<=6 months after the completion of the adjuvant chemotherapy, then the adjuvant chemotherapy is considered as the systemic chemotherapy to the disease.

  2. Systemic anti cancer therapy completed within a minimum of 5 half lives of study enrollment.
  3. Prior therapy with an antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways, including, but not limited to, anti programmed cell death protein 1 (anti PD 1), anti programmed cell death protein ligand 1 (anti PD L1), anti PD L2, anti cluster of differentiation 137 (anti CD137), or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody.
  4. Known epidermal growth factor receptor (EGFR) activating mutations; known prior therapy with EGFR TKI(s) (the prior treatment with brigatinib is allowed as an ALK TKI).
  5. Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.
  6. Radiation therapy within 2 weeks prior to enrollment. Palliative radiation must have been completed at least 48 hours prior to enrollment. Stereotactic or partial brain irradiation must have completed at least 2 weeks prior to enrollment. Whole brain irradiation must have completed at least 4 weeks prior to enrollment.
  7. Spinal cord compression unless the subject has good pain control attained through therapy, and there is complete recovery of neurological function for the 4 weeks prior to enrollment.
  8. Gastrointestinal abnormalities, including inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection or lap band; active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer disease in the past 6 months; malabsorption syndromes.
  9. Known prior or suspected severe to lorlatinib or any component in the formulation; known prior therapy with lorlatinib.
  10. Active and bacterial, fungal, or viral infection including virus (HBV), virus (HCV), known (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
  11. Clinically significant cardiovascular disease (both arterial and venous) and non vascular cardiac conditions, (active or within 3 months prior to enrollment, which may include, but not are limited to:

    • Arterial disease such as cerebral vascular accident/stroke (including -TIA), myocardial infarction, unstable angina;
    • Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary embolism;
    • Nonvascular cardiac disease such as congestive heart failure ( Classification Class ≥ II), second degree or third degree atrioventricular block (unless paced) or any AV block with PR interval >220 msec; or
    • Ongoing cardiac dysrhythmias of Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as \<50 bpm (unless subject is otherwise healthy such as long distance runners, etc.), machine read (ECG) with >470 msec, or congenital long QT syndrome.
  12. Subject with predisposing characteristics for acute pancreatitis according to investigator judgment, including but not limited to uncontrolled hyperglycemia, current gallstone disease, in the last month prior to enrollment.
  13. History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.
  14. Evidence of active (other than NSCLC, non melanoma skin cancer, or localized and presumed cured prostate cancer or any in situ cancer which does not currently require treatment) within the last 3 years prior to enrollment.
  15. Concurrent use of any of the following food or drugs (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days prior to the first dose of administration of lorlatinib:

    1. Known strong inhibitors (eg, strong CYP3A inhibitors: grapefruit juice or grapefruit/grapefruit related citrus fruits [eg, Seville oranges, pomelos], boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole, ritonavir alone and with danoprevir or elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir, troleandomycin, and voriconazole). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed;
    2. Known CYP3A substrates with narrow therapeutic index, such as astemizole*, terfenadine*, cisapride*, pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine) (*withdrawn from US market);
    3. Known strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort);
    4. Known P glycoprotein (P gp) substrates with a narrow therapeutic index (eg, digoxin).
  16. Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator and/or the sponsor, would make the subject inappropriate for entry into this study.
  17. Subject who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  18. Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.
  19. Pregnant female participants; breastfeeding female participants; fertile male participants and female participants of who are unwilling or unable to use a highly effective method of as outlined in this protocol for the duration of the study and for at least 97 days if male or 35 days if female, after the last dose of investigational product.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Lorlatinib

    Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously

    Drug: Lorlatinib

Interventions

  • ALK inhibitor-treated ALK-positive NSCL treatment

    Also known as: PF-06463922

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (Cohort 1)

    Objective response rate (ORR) was defined as the percentage of participants with a best overall confirmed response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR was defined as a greater than equal to (\>=) 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Independent Central Radiology (ICR) was used for disease progression assessment.

    Time frame: From Cycle 1 Day 1 to documented progression of disease by ICR (up to 67 weeks)

Secondary outcomes

  1. Percentage of Participants With Objective Response (Cohort 2)

    ORR was defined as the percentage of participants with a best overall confirmed response of CR or PR according to RECIST version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. ICR was used for disease progression assessment.

    Time frame: From Cycle 1 Day 1 to documented progression of disease by ICR (up to 67 weeks)

  2. Progression-Free Survival (PFS) Based on ICR Assessment

    PFS was defined as the time from first dose to first documentation of objective disease progression (PD) or to death due to any cause, whichever came first. PD: at least a \>=20 percent (%) increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, PD was defined as unequivocal progression of existing non-target lesions, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Analysis was performed using Kaplan Meier method. ICR was used for disease progression assessment.

    Time frame: From first dose (Cycle 1 Day 1) to documented PD by ICR, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)

  3. Progression-Free Survival Based on Investigator Assessment

    PFS was defined as the time from first dose to first documentation of objective PD or to death due to any cause, whichever came first. PD: at least a \>=20 % increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, PD was defined as unequivocal progression of existing non-target lesions, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Analysis was performed using Kaplan Meier method. Investigator assessment was used for disease progression assessment.

    Time frame: From first dose (Cycle 1 Day 1) to documented progression of disease by investigator, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)

  4. Overall Survival

    Overall survival was defined as the time from first dose to the date of death due to any cause. Analysis was performed using Kaplan Meier method.

    Time frame: From first dose (Cycle 1 Day 1) to date of death due to any cause (up to 271 weeks of treatment exposure)

  5. Percentage of Participants With Intracranial Objective Response (IC-OR) Based on ICR Assessment

    IC-OR: percentage of participants with a best overall confirmed intracranial response of CR or PR according to RECIST version 1.1 relative to total participants in the analysis population but limited to intra cranial lesions only in participants with central nervous system metastases. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>= 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. 95% CI was based on Clopper-Pearson method.

    Time frame: From first dose (Cycle 1 Day 1) to documented PD by ICR (up to 271 weeks of treatment exposure)

  6. Percentage of Participants With Intracranial Objective Response Based on Investigator Assessment

    IC-OR: percentage of participants with a best overall confirmed intracranial response of CR or PR according to RECIST version 1.1 relative to total participants in the analysis population but limited to intra cranial lesions only in participants with central nervous system metastases. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>= 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. 95% CI was based on Clopper-Pearson method

    Time frame: From first dose (Cycle 1 Day 1) to documented progression of disease by investigator (up to 271 weeks of treatment exposure)

  7. Duration of Response (DOR) Based on ICR Assessment

    DOR: time from first documentation of CR or PR to first documentation of PD or death due to any cause, whichever occurred first. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm. PR:\>=30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. PD:\>=20 % increase in sum of longest dimensions of target lesions taking as a reference smallest sum of longest dimensions recorded since treatment started, or the appearance of one or more new lesions. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5 mm and for non-target lesions PD: unequivocal progression of existing non-target lesions or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at time of analysis were censored at date of last tumor assessment. Analysis was performed using Kaplan Meier method.

    Time frame: From first documentation of CR or PR to documented progression of disease by ICR, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)

  8. DOR Based on Investigator Assessment

    DOR: time from first documentation of CR or PR to first documentation of PD or death due to any cause, whichever occurred first. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm. PR:\>=30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. PD:\>=20 % increase in sum of longest dimensions of target lesions taking as a reference smallest sum of longest dimensions recorded since treatment started, or the appearance of one or more new lesions. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5 mm and for non-target lesions PD: unequivocal progression of existing non-target lesions or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at time of analysis were censored at date of last tumor assessment. Analysis was performed using Kaplan Meier method.

    Time frame: From first documentation of CR or PR to documented PD by investigator, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure

  9. Duration of Intracranial Response Based on ICR Assessment

    Duration of intracranial response: time from first documentation of CR or PR considering only lesions having disease site=brain to first documentation of PD or death due to any cause, whichever occurred first, participants who had at least 1 intracranial lesion.CR: disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in \<10mm.PR:\>=30% decrease in the sum of the longest dimensions of target lesions taking reference the baseline sum longest dimension. PD:\>=20% increase in sum of longest dimensions of target lesion, or appearance of one or more new lesion. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5mm and for non-target lesion PD: unequivocal progression of existing non-target lesion, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan Meier method was used.

    Time frame: From first documentation of CR or PR to documented progression of disease by ICR, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)

  10. Duration of Intracranial Response Based on Investigator Assessment

    Duration of intracranial response: time from first documentation of CR or PR considering only lesions having disease site=brain to first documentation of PD or death due to any cause, whichever occurred first, participants who had at least 1 intracranial lesion.CR: disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in \<10mm.PR:\>=30% decrease in the sum of the longest dimensions of target lesions taking reference the baseline sum longest dimension. PD:\>=20% increase in sum of longest dimensions of target lesion or appearance of one or more new lesion. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5mm and for non-target lesion PD: unequivocal progression of existing non-target lesion, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan Meier method was used.

    Time frame: From first documentation of CR or PR to documented progression of disease by investigator, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)

  11. Time to Tumor Response Based on ICR Assessment

    Time to tumor response was defined as the time from first dose to first documentation of objective tumor response CR or PR. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: From first dose (Cycle 1 Day 1) to first documented CR or PR (up to 271 weeks of treatment exposure)

  12. Time to Tumor Response Based on Investigator Assessment

    Time to tumor response was defined as the time from first dose to first documentation of objective tumor response CR or PR. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: From first dose (Cycle 1 Day 1) to documented first CR or PR (up to 271 weeks of treatment exposure)

  13. Number of Participants With Adverse Events (AEs)

    AE:any untoward medical occurrence in a study participant administered a product or medical device;event did not necessarily have a causal relationship with treatment or usage.Serious AE:any untoward medical occurrence at any dose resulted in death;life-threatening;required inpatient or prolongation of existing hospitalization;persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important event.AEs were graded by the National Cancer Institute Common Terminology Criteria AE(NCICTCAE)v4.03 where,Grade(G)1:mild AE;G2:moderate;G3:severe;G4:life-threatening consequences,urgent intervention indicated;G5:death related to AE. Focus of AE summaries was on treatment-emergent AE(TEAE).AE was considered TEAE if the event occurred during the on-treatment period.On-treatment:time from first dose of study treatment through end of study follow-up(i.e.,up to 28 days after last dose of treatment. Participant with G3or4 and5 AEs were reported.

    Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks

  14. Number of Participants With Central Nervous System-Related Adverse Events

    An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily have a causal relationship with the treatment or usage. The central-nervous system-related AEs included AEs under the cluster terms of mood effects, cognitive effects, psychotic effects, and speech effects.

    Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks

  15. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

    Laboratory tests included hematology, chemistry and lipids. Laboratory test results were graded according to NCI CTCAE version 4.03, where Grade 0: no AE, Grade 1 : mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Shifts from Grade \<=2 at baseline to Grade 3 or 4 post-baseline were considered clinically significant. Only categories with non-zero values were reported in this outcome measure.

    Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks

  16. Number of Participants With Vital Signs Data Meeting Pre-specified Criteria

    Vital signs evaluation included diastolic blood pressure (DBP), systolic blood pressure (SBP), pulse rate and weight. Blood pressure and pulse rate were recorded in sitting position after the participant had been sitting quietly for at least 5 minutes. The pre-specified criteria included: sitting SBP change \>=40 millimeters of mercury (mmHg) increase, \>=40 mmHg decrease; sitting DBP change \>=20 mmHg increase, change \>=20 mmHg decrease, or change \>=60 mmHg increase; sitting pulse rate value \<50 beats per minute (bpm), \>120 bpm, change \>=30 bpm increase, or change \>=30 bpm decrease; weight 10% \<= change \<20% increase, change \>=20% increase or change \>=10% decrease. One participant can have more than one vital sign data meeting pre-specified criteria.

    Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks

  17. Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria

    The QT intervals were corrected for heart rate (QTc) using standard correction factors (ie, QTcF \[Fridericia's\], QTcB \[Bazett's\], and possibly a study-specified factor, as appropriate). The pre-specified criteria included: PR interval change \>= 50% and baseline \<200 msec, change \>=25% and baseline \>=200 msec; QRS interval change \>=50% and baseline \<100 msec, change \>=25% and baseline \>=100 msec; QTcB values \<=450 msec, 450 \< Value \<= 480 msec, 480 \< Value \<= 500 msec, value \>500 msec, change \<=30 msec, 30 \< Change \<= 60 msec, change \>60 msec; QTcF value \<=450 msec, 450 \< Value \<= 480 msec, 480 \< Value \<= 500 msec, Value \> 500 msec, change \<=30 msec, 30 \< Change \<=60 msec and change \>60 msec. . One participant can have more than one ECG data meeting pre-specified criteria.

    Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks

  18. Number of Participants With Left Ventricular Ejection Fraction (LVEF) Meeting Pre-specified Criteria

    Echocardiogram or multigated acquisition scan were performed to monitor LVEF. Pre-specified criteria included shift from baseline normal to post-baseline below lower limit of normal (LLN) \>=20-point decrease from baseline in LVEF% .

    Time frame: From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks

  19. Cycle 1 Day 1 Maximum Plasma Concentration (Cmax)

    The loratinib Cmax was estimated using non-compartmental analysis.

    Time frame: At pre-dose, 0.5, 1, 2, 3, 4, 6 ,8, 9 and 24 hours on Cycle 1 Day 1

  20. Cycle 1 Day 1 Time to Cmax (Tmax)

    The loratinib Tmax was estimated using non-compartmental analysis.

    Time frame: At pre-dose, 0.5, 1, 2, 3, 4, 6 ,8, 9 and 24 hours on Cycle 1 Day 1

  21. Cycle 1 Day 1 Area Under the Plasma Concentration Versus Time Profile Within A Dose Interval (AUCtau)

    The loratinib AUCtau was estimated using non-compartmental analysis.

    Time frame: At pre-dose, 0.5, 1, 2, 3, 4, 6 ,8, 9 and 24 hours on Cycle 1 Day 1

  22. Steady-State Cmax

    The loratinib Cmax was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.

    Time frame: At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1

  23. Steady-State Tmax

    The loratinib Tmax was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.

    Time frame: At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1

  24. Steady-State AUCtau

    The loratinib AUCtau was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.

    Time frame: At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1

  25. Apparent Clearance (CL/F)

    The loratinib CL/F was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.

    Time frame: At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1

  26. Observed Accumulation Ratio (Rac)

    The loratinib Rac was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.

    Time frame: At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1

Other outcomes

  1. Percentage of Participants With Objective Response (Cohort 1)-Final Analysis

    ORR was defined as the percentage of participants with a best overall confirmed response of CR or PR according to RECIST version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. ICR was used for disease progression assessment.

    Time frame: From first dose (Cycle 1 Day 1) to documented disease progression by ICR (up to 271 weeks of treatment exposure)

07

Results

Posted Oct 26, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started6742
Completed00
Not completed6742
Withdrew: Participant transition to rollover study269
Withdrew: Global deterioration of health status22
Withdrew: Progressive disease2821
Withdrew: Death66
Withdrew: Adverse event12
Withdrew: Withdrawal by subject21
Withdrew: Participant was unwilling to come to site visit01
Withdrew: No longer benefit from lorlatinib20

Outcome measures

PrimaryPercentage of Participants With Objective Response (Cohort 1)

Objective response rate (ORR) was defined as the percentage of participants with a best overall confirmed response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR was defined as a greater than equal to (\>=) 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Independent Central Radiology (ICR) was used for disease progression assessment.

Time frame:
From Cycle 1 Day 1 to documented progression of disease by ICR (up to 67 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (Cohort 1)
Percentage of participantsCohort 1
Percentage of Participants With Objective Response (Cohort 1)70.1 (57.7 to 80.7)
Statistical analysis
  • Cohort 1 · Fisher Exact · p = <0.0001
Other pre-specifiedPercentage of Participants With Objective Response (Cohort 1)-Final Analysis

ORR was defined as the percentage of participants with a best overall confirmed response of CR or PR according to RECIST version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. ICR was used for disease progression assessment.

Time frame:
From first dose (Cycle 1 Day 1) to documented disease progression by ICR (up to 271 weeks of treatment exposure)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (Cohort 1)-Final Analysis
Percentage of participantsCohort 1
Percentage of Participants With Objective Response (Cohort 1)-Final Analysis79.1 (67.4 to 88.1)
SecondaryPercentage of Participants With Objective Response (Cohort 2)

ORR was defined as the percentage of participants with a best overall confirmed response of CR or PR according to RECIST version 1.1 relative to the total participants in the analysis population. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. ICR was used for disease progression assessment.

Time frame:
From Cycle 1 Day 1 to documented progression of disease by ICR (up to 67 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (Cohort 2)
Percentage of participantsCohort 2
Percentage of Participants With Objective Response (Cohort 2)47.6 (32.0 to 63.6)
SecondaryProgression-Free Survival (PFS) Based on ICR Assessment

PFS was defined as the time from first dose to first documentation of objective disease progression (PD) or to death due to any cause, whichever came first. PD: at least a \>=20 percent (%) increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, PD was defined as unequivocal progression of existing non-target lesions, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Analysis was performed using Kaplan Meier method. ICR was used for disease progression assessment.

Time frame:
From first dose (Cycle 1 Day 1) to documented PD by ICR, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)
Reported as:
Median · Months
Progression-Free Survival (PFS) Based on ICR Assessment
MonthsCohort 1Cohort 2
Progression-Free Survival (PFS) Based on ICR Assessment26.3 (16.6 to NA)5.6 (2.9 to 12.4)
SecondaryProgression-Free Survival Based on Investigator Assessment

PFS was defined as the time from first dose to first documentation of objective PD or to death due to any cause, whichever came first. PD: at least a \>=20 % increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, PD was defined as unequivocal progression of existing non-target lesions, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Analysis was performed using Kaplan Meier method. Investigator assessment was used for disease progression assessment.

Time frame:
From first dose (Cycle 1 Day 1) to documented progression of disease by investigator, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)
Reported as:
Median · Months
Progression-Free Survival Based on Investigator Assessment
MonthsCohort 1Cohort 2
Progression-Free Survival Based on Investigator Assessment26.3 (15.2 to 52.4)6.9 (4.2 to 13.7)
SecondaryOverall Survival

Overall survival was defined as the time from first dose to the date of death due to any cause. Analysis was performed using Kaplan Meier method.

Time frame:
From first dose (Cycle 1 Day 1) to date of death due to any cause (up to 271 weeks of treatment exposure)
Reported as:
Median · Months
Overall Survival
MonthsCohort 1Cohort 2
Overall SurvivalNA (42.7 to NA)21.9 (11.9 to 44.1)
SecondaryPercentage of Participants With Intracranial Objective Response (IC-OR) Based on ICR Assessment

IC-OR: percentage of participants with a best overall confirmed intracranial response of CR or PR according to RECIST version 1.1 relative to total participants in the analysis population but limited to intra cranial lesions only in participants with central nervous system metastases. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>= 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. 95% CI was based on Clopper-Pearson method.

Time frame:
From first dose (Cycle 1 Day 1) to documented PD by ICR (up to 271 weeks of treatment exposure)
Reported as:
Number · Percentage of participants
Percentage of Participants With Intracranial Objective Response (IC-OR) Based on ICR Assessment
Percentage of participantsCohort 1Cohort 2
Percentage of Participants With Intracranial Objective Response (IC-OR) Based on ICR Assessment83.8 (68.0 to 93.8)50.0 (28.2 to 71.8)
SecondaryPercentage of Participants With Intracranial Objective Response Based on Investigator Assessment

IC-OR: percentage of participants with a best overall confirmed intracranial response of CR or PR according to RECIST version 1.1 relative to total participants in the analysis population but limited to intra cranial lesions only in participants with central nervous system metastases. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>= 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. 95% CI was based on Clopper-Pearson method

Time frame:
From first dose (Cycle 1 Day 1) to documented progression of disease by investigator (up to 271 weeks of treatment exposure)
Reported as:
Number · Percentage of participants
Percentage of Participants With Intracranial Objective Response Based on Investigator Assessment
Percentage of participantsCohort 1Cohort 2
Percentage of Participants With Intracranial Objective Response Based on Investigator Assessment63.4 (46.9 to 77.9)33.3 (15.6 to 55.3)
SecondaryDuration of Response (DOR) Based on ICR Assessment

DOR: time from first documentation of CR or PR to first documentation of PD or death due to any cause, whichever occurred first. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm. PR:\>=30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. PD:\>=20 % increase in sum of longest dimensions of target lesions taking as a reference smallest sum of longest dimensions recorded since treatment started, or the appearance of one or more new lesions. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5 mm and for non-target lesions PD: unequivocal progression of existing non-target lesions or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at time of analysis were censored at date of last tumor assessment. Analysis was performed using Kaplan Meier method.

Time frame:
From first documentation of CR or PR to documented progression of disease by ICR, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)
Reported as:
Median · Months
Duration of Response (DOR) Based on ICR Assessment
MonthsCohort 1Cohort 2
Duration of Response (DOR) Based on ICR Assessment31.7 (18.0 to NA)10.4 (2.9 to NA)
SecondaryDOR Based on Investigator Assessment

DOR: time from first documentation of CR or PR to first documentation of PD or death due to any cause, whichever occurred first. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm. PR:\>=30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. PD:\>=20 % increase in sum of longest dimensions of target lesions taking as a reference smallest sum of longest dimensions recorded since treatment started, or the appearance of one or more new lesions. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5 mm and for non-target lesions PD: unequivocal progression of existing non-target lesions or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at time of analysis were censored at date of last tumor assessment. Analysis was performed using Kaplan Meier method.

Time frame:
From first documentation of CR or PR to documented PD by investigator, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure
Reported as:
Median · Months
DOR Based on Investigator Assessment
MonthsCohort 1Cohort 2
DOR Based on Investigator Assessment20.9 (12.4 to NA)20.8 (5.6 to NA)
SecondaryDuration of Intracranial Response Based on ICR Assessment

Duration of intracranial response: time from first documentation of CR or PR considering only lesions having disease site=brain to first documentation of PD or death due to any cause, whichever occurred first, participants who had at least 1 intracranial lesion.CR: disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in \<10mm.PR:\>=30% decrease in the sum of the longest dimensions of target lesions taking reference the baseline sum longest dimension. PD:\>=20% increase in sum of longest dimensions of target lesion, or appearance of one or more new lesion. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5mm and for non-target lesion PD: unequivocal progression of existing non-target lesion, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan Meier method was used.

Time frame:
From first documentation of CR or PR to documented progression of disease by ICR, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)
Reported as:
Median · Months
Duration of Intracranial Response Based on ICR Assessment
MonthsCohort 1Cohort 2
Duration of Intracranial Response Based on ICR AssessmentNA (30.6 to NA)NA (5.6 to NA)
SecondaryDuration of Intracranial Response Based on Investigator Assessment

Duration of intracranial response: time from first documentation of CR or PR considering only lesions having disease site=brain to first documentation of PD or death due to any cause, whichever occurred first, participants who had at least 1 intracranial lesion.CR: disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in \<10mm.PR:\>=30% decrease in the sum of the longest dimensions of target lesions taking reference the baseline sum longest dimension. PD:\>=20% increase in sum of longest dimensions of target lesion or appearance of one or more new lesion. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5mm and for non-target lesion PD: unequivocal progression of existing non-target lesion, or the appearance of \>=1 new lesion. Participants without documentation of PD, or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan Meier method was used.

Time frame:
From first documentation of CR or PR to documented progression of disease by investigator, death due to any cause or date of censoring, whichever occurred first (up to 271 weeks of treatment exposure)
Reported as:
Median · Months
Duration of Intracranial Response Based on Investigator Assessment
MonthsCohort 1Cohort 2
Duration of Intracranial Response Based on Investigator AssessmentNA (15.1 to NA)NA (8.3 to NA)
SecondaryTime to Tumor Response Based on ICR Assessment

Time to tumor response was defined as the time from first dose to first documentation of objective tumor response CR or PR. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
From first dose (Cycle 1 Day 1) to first documented CR or PR (up to 271 weeks of treatment exposure)
Reported as:
Median · Months
Time to Tumor Response Based on ICR Assessment
MonthsCohort 1Cohort 2
Time to Tumor Response Based on ICR Assessment1.4 (1.2 to 17.9)1.4 (1.2 to 6.9)
SecondaryTime to Tumor Response Based on Investigator Assessment

Time to tumor response was defined as the time from first dose to first documentation of objective tumor response CR or PR. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
From first dose (Cycle 1 Day 1) to documented first CR or PR (up to 271 weeks of treatment exposure)
Reported as:
Median · Months
Time to Tumor Response Based on Investigator Assessment
MonthsCohort 1Cohort 2
Time to Tumor Response Based on Investigator Assessment1.4 (1.2 to 27.6)1.4 (1.2 to 17.9)
SecondaryNumber of Participants With Adverse Events (AEs)

AE:any untoward medical occurrence in a study participant administered a product or medical device;event did not necessarily have a causal relationship with treatment or usage.Serious AE:any untoward medical occurrence at any dose resulted in death;life-threatening;required inpatient or prolongation of existing hospitalization;persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important event.AEs were graded by the National Cancer Institute Common Terminology Criteria AE(NCICTCAE)v4.03 where,Grade(G)1:mild AE;G2:moderate;G3:severe;G4:life-threatening consequences,urgent intervention indicated;G5:death related to AE. Focus of AE summaries was on treatment-emergent AE(TEAE).AE was considered TEAE if the event occurred during the on-treatment period.On-treatment:time from first dose of study treatment through end of study follow-up(i.e.,up to 28 days after last dose of treatment. Participant with G3or4 and5 AEs were reported.

Time frame:
From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsCohort 1Cohort 2
All-causality TEAEs6742
Treatment-related TEAEs6742
All-causality serious AEs2316
Treatment-related serious AEs115
All-causalities maximum Grade 3 or 4 AEs4925
Treatment-related Grade 3 or 4 AEs4619
All-causality Grade 5 AEs47
Treatment-related Grade 5 AEs00
SecondaryNumber of Participants With Central Nervous System-Related Adverse Events

An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily have a causal relationship with the treatment or usage. The central-nervous system-related AEs included AEs under the cluster terms of mood effects, cognitive effects, psychotic effects, and speech effects.

Time frame:
From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Reported as:
Count of participants · Participants
Number of Participants With Central Nervous System-Related Adverse Events
ParticipantsCohort 1Cohort 2
Cognitive Effects21
Mood Effects12
Speech Effects01
Psychotic Effects10
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

Laboratory tests included hematology, chemistry and lipids. Laboratory test results were graded according to NCI CTCAE version 4.03, where Grade 0: no AE, Grade 1 : mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Shifts from Grade \<=2 at baseline to Grade 3 or 4 post-baseline were considered clinically significant. Only categories with non-zero values were reported in this outcome measure.

Time frame:
From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities
ParticipantsCohort 1Cohort 2
Anemia: Grade 0 to Grade 3 or 430
Anemia:Grade 1 to Grade 3 or 423
Anemia:Grade 2 to Grade 3 or 411
Lymphocyte count decreased Grade 0 to Grade 3 or 430
Lymphocyte count decreased:Grade 1 to Grade 3 or 410
Platelet count decreased: Grade 0 to Grade 3 or 421
Alanine aminotransferase increased: Grade 0 to Grade 3 or 420
Alanine aminotransferase increased:Grade 1 to Grade 3 or 420
Alkaline phosphatase increased: Grade 0 to Grade 3 or 410
Aspartate aminotransferase increased: Grade 0 to Grade 3 or 421
Aspartate aminotransferase increased:Grade 1 to Grade 3 or 410
Blood bilirubin increased: Grade 0 to Grade 3 or 410
Blood bilirubin increased:Grade 1 to Grade 3 or 401
CPK increased: Grade 0 to Grade 3 or 401
CPK increased:Grade 2 to Grade 3 or 410
Creatinine increased: Grade 0 to Grade 3 or 411
GGT increased: Grade 0 to Grade 3 or 432
GGT increased:Grade 1 to Grade 3 or 420
Hypercalcemia: Grade 0 to Grade 3 or 401
Hyperglycemia: Grade 0 to Grade 3 or 460
Hyperglycemia:Grade 1 to Grade 3 or 411
Hypermagnesemia: Grade 0 to Grade 3 or 471
Hypocalcemia: Grade 0 to Grade 3 or 401
Hypokalemia: Grade 0 to Grade 3 or 422
Hypokalemia:Grade 2 to Grade 3 or 410
Hyponatremia: Grade 0 to Grade 3 or 411
Hyponatremia:Grade 1 to Grade 3 or 401
Hypophosphatemia: Grade 0 to Grade 3 or 441
Hypophosphatemia:Grade 1 to Grade 3 or 401
Lipase increased: Grade 0 to Grade 3 or 452
Lipase increased:Grade 1 to Grade 3 or 410
Serum amylase increased: Grade 0 to Grade 3 or 411
Cholesterol high: Grade 0 to Grade 3 or 4121
Cholesterol high:Grade 1 to Grade 3 or 463
Cholesterol high:Grade 2 to Grade 3 or 410
Hypertriglyceridemia: Grade 0 to Grade 3 or 4193
Hypertriglyceridemia:Grade 1 to Grade 3 or 496
Hypertriglyceridemia:Grade 2 to Grade 3 or 431
SecondaryNumber of Participants With Vital Signs Data Meeting Pre-specified Criteria

Vital signs evaluation included diastolic blood pressure (DBP), systolic blood pressure (SBP), pulse rate and weight. Blood pressure and pulse rate were recorded in sitting position after the participant had been sitting quietly for at least 5 minutes. The pre-specified criteria included: sitting SBP change \>=40 millimeters of mercury (mmHg) increase, \>=40 mmHg decrease; sitting DBP change \>=20 mmHg increase, change \>=20 mmHg decrease, or change \>=60 mmHg increase; sitting pulse rate value \<50 beats per minute (bpm), \>120 bpm, change \>=30 bpm increase, or change \>=30 bpm decrease; weight 10% \<= change \<20% increase, change \>=20% increase or change \>=10% decrease. One participant can have more than one vital sign data meeting pre-specified criteria.

Time frame:
From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria
ParticipantsCohort 1Cohort 2
Sitting SBP change >=40 mmHg increase101
Sitting SBP change >=40 mmHg decrease20
Sitting DBP change >=20 mmHg increase2610
Sitting DBP change >=20 mmHg decrease127
Sitting DBP change >=60 mmHg increase00
Sitting pulse rate value <50 bpm00
Sitting pulse rate value >120 bpm53
Sitting pulse rate change >=30 mmHg increase185
Sitting pulse rate change >=30 mmHg decrease57
weight 10% <= change <20% kg increase4322
Weight change >=20% kg increase146
Weight change >=10% kg decrease32
SecondaryNumber of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria

The QT intervals were corrected for heart rate (QTc) using standard correction factors (ie, QTcF \[Fridericia's\], QTcB \[Bazett's\], and possibly a study-specified factor, as appropriate). The pre-specified criteria included: PR interval change \>= 50% and baseline \<200 msec, change \>=25% and baseline \>=200 msec; QRS interval change \>=50% and baseline \<100 msec, change \>=25% and baseline \>=100 msec; QTcB values \<=450 msec, 450 \< Value \<= 480 msec, 480 \< Value \<= 500 msec, value \>500 msec, change \<=30 msec, 30 \< Change \<= 60 msec, change \>60 msec; QTcF value \<=450 msec, 450 \< Value \<= 480 msec, 480 \< Value \<= 500 msec, Value \> 500 msec, change \<=30 msec, 30 \< Change \<=60 msec and change \>60 msec. . One participant can have more than one ECG data meeting pre-specified criteria.

Time frame:
From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria
ParticipantsCohort 1Cohort 2
PR interval change >=50% and baseline <200 msec41
PR interval change >=25% and baseline >=200 msec00
QRS interval change >=50% and baseline<100 msec11
QRS interval change >=25% and baseline >=100 msec20
QTcB value <=450 msec2727
QTcB 450 < Value <= 480 msec269
QTcB 480 < Value <= 500 msec53
QTcB value >500 msec93
QTcB change <=30 msec3125
QTcB 30 < Change <= 60 msec2414
QTcB change >60 msec123
QTcF value <=450 msec4935
QTcF 450 < Value <= 480 msec136
QTcF 480 < Value <= 500 msec11
QTcF value >500 msec40
QTcF change <=30 msec3929
QTcF 30 < Change <= 60 msec209
QTcF change >60 msec84
SecondaryNumber of Participants With Left Ventricular Ejection Fraction (LVEF) Meeting Pre-specified Criteria

Echocardiogram or multigated acquisition scan were performed to monitor LVEF. Pre-specified criteria included shift from baseline normal to post-baseline below lower limit of normal (LLN) \>=20-point decrease from baseline in LVEF% .

Time frame:
From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks
Reported as:
Count of participants · Participants
Number of Participants With Left Ventricular Ejection Fraction (LVEF) Meeting Pre-specified Criteria
ParticipantsCohort 1Cohort 2
LVEF change from baseline normal to post-baseline below LLN70
LVEF >=20-point decrease from baseline30
SecondaryCycle 1 Day 1 Maximum Plasma Concentration (Cmax)

The loratinib Cmax was estimated using non-compartmental analysis.

Time frame:
At pre-dose, 0.5, 1, 2, 3, 4, 6 ,8, 9 and 24 hours on Cycle 1 Day 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cycle 1 Day 1 Maximum Plasma Concentration (Cmax)
nanogram per milliliter (ng/mL)Cohort 1Cohort 2
Cycle 1 Day 1 Maximum Plasma Concentration (Cmax)1004 ± 421074 ± 58
SecondaryCycle 1 Day 1 Time to Cmax (Tmax)

The loratinib Tmax was estimated using non-compartmental analysis.

Time frame:
At pre-dose, 0.5, 1, 2, 3, 4, 6 ,8, 9 and 24 hours on Cycle 1 Day 1
Reported as:
Median · hour
Cycle 1 Day 1 Time to Cmax (Tmax)
hourCohort 1Cohort 2
Cycle 1 Day 1 Time to Cmax (Tmax)1.02 (0.500 to 3.12)1.45 (0.483 to 4.00)
SecondaryCycle 1 Day 1 Area Under the Plasma Concentration Versus Time Profile Within A Dose Interval (AUCtau)

The loratinib AUCtau was estimated using non-compartmental analysis.

Time frame:
At pre-dose, 0.5, 1, 2, 3, 4, 6 ,8, 9 and 24 hours on Cycle 1 Day 1
Reported as:
Geometric mean · nanogram*hour per milliliter (ng.hr/mL)
Cycle 1 Day 1 Area Under the Plasma Concentration Versus Time Profile Within A Dose Interval (AUCtau)
nanogram*hour per milliliter (ng.hr/mL)Cohort 1Cohort 2
Cycle 1 Day 1 Area Under the Plasma Concentration Versus Time Profile Within A Dose Interval (AUCtau)7310 ± 177778 ± 39
SecondarySteady-State Cmax

The loratinib Cmax was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.

Time frame:
At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1
Reported as:
Geometric mean · ng/mL
Steady-State Cmax
ng/mLCohort 1Cohort 2
Steady-State Cmax643.9 ± 50795.9 ± 40
SecondarySteady-State Tmax

The loratinib Tmax was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.

Time frame:
At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1
Reported as:
Median · hour
Steady-State Tmax
hourCohort 1Cohort 2
Steady-State Tmax1.53 (0.533 to 3.03)1.88 (0.500 to 8.02)
SecondarySteady-State AUCtau

The loratinib AUCtau was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.

Time frame:
At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1
Reported as:
Geometric mean · ng*hr/mL
Steady-State AUCtau
ng*hr/mLCohort 1Cohort 2
Steady-State AUCtau5388 ± 376801 ± 40
SecondaryApparent Clearance (CL/F)

The loratinib CL/F was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.

Time frame:
At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1
Reported as:
Geometric mean · Liter per hour (L/hr)
Apparent Clearance (CL/F)
Liter per hour (L/hr)Cohort 1Cohort 2
Apparent Clearance (CL/F)18.55 ± 3714.71 ± 40
SecondaryObserved Accumulation Ratio (Rac)

The loratinib Rac was estimated using non-compartmental analysis. Steady-state was reached on Cycle 1 Day 15.

Time frame:
At Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours on Day 15 of Cycle 1
Reported as:
Geometric mean · Ratio
Observed Accumulation Ratio (Rac)
RatioCohort 1Cohort 2
Observed Accumulation Ratio (Rac)0.7371 ± 470.9578 ± 33

Adverse events

Collected over From start of study treatment (Cycle 1 Day 1) up to 28 days after the last administration of the investigational product, up to approximately 275 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 128/67 (41.8%)23/67 (34.3%)67/67 (100%)
Cohort 226/42 (61.9%)16/42 (38.1%)42/42 (100%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventCohort 1Cohort 2
PneumoniaInfections and infestations3/675/42
PyrexiaGeneral disorders0/672/42
Respiratory failureRespiratory, thoracic and mediastinal disorders1/672/42
HyperglycaemiaMetabolism and nutrition disorders2/670/42
Cerebral infarctionNervous system disorders2/670/42
PneumonitisRespiratory, thoracic and mediastinal disorders2/670/42
DeathGeneral disorders0/671/42
Sudden deathGeneral disorders0/671/42
Liver injuryHepatobiliary disorders0/671/42
Febrile infectionInfections and infestations0/671/42
Most frequent other events
Showing 10 of 84
Most frequent other events
EventCohort 1Cohort 2
HypertriglyceridaemiaMetabolism and nutrition disorders60/6732/42
Weight increasedInvestigations49/6719/42
HypercholesterolaemiaMetabolism and nutrition disorders41/6729/42
Aspartate aminotransferase increasedInvestigations40/6718/42
Alanine aminotransferase increasedInvestigations38/6719/42
AnaemiaBlood and lymphatic system disorders31/6715/42
HyperglycaemiaMetabolism and nutrition disorders31/676/42
Blood cholesterol increasedInvestigations29/6714/42
Gamma-glutamyltransferase increasedInvestigations28/6712/42
HypoalbuminaemiaMetabolism and nutrition disorders21/679/42

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Total
Mean50.4 ± 10.8552.1 ± 13.3651.0 ± 11.84
Age, Customized
Age, Customized(Participants)Cohort 1Cohort 2Total
<18 years000
Between 18 and 65 years613596
>65 years6713
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female332356
Male341953
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Total
Asian — Chinese6742109
08

Study locations

21 sites
  • Gaoxin Hospital of The First Affilated Hospital of Anhui Medical University
    Hefei, Anhui 230088, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Fujian Province Oncology Hospital
    Fuzhou, Fujian 350014, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • Hunan Provincial Tumor Hospital/Division of Oncology
    Changsha, Hunan 410013, China
  • The first hospital of jilin university
    Changchun, Jilin 130021, China
  • Jilin Provincial Cancer Hospital
    Changchun, Jilin 130103, China
  • Tangdu Hospital of Fourth Military Medical University
    Xi’an, Shanxi 710000, China
  • Sichuan Province Cancer Hospital/Department of Pulmonary Tumor
    Chengdu, Sichuan 610041, China
  • West China Hospital, Sichuan University, Cancer center
    Chengdu, Sichuan 610041, China
  • The Second Affiliated Hospital of Zhejiang University College of Medicine
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • Fifth Medical Center of PLA General Hospital
    Beijing, 100071, China
  • Beijing Chest Hospital, Capital Medical University
    Beijing, 101149, China
  • Guangdong Provincial People's Hospital
    Guangzhou, 510000, China
  • The First Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, 310003, China
  • General Hospital of Eastern Theater Command
    Nanjing, China
  • Shanghai Chest Hospital
    Shanghai, 200030, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Zhongshan Hospital, Fudan University
    Shanghai, 200032, China
09

References and documents

Publications

  • Lu S, Zhou Q, Liu X, Du Y, Fan Y, Cheng Y, He S, Zhao H, Li H, Wu YL. Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer. Clin Lung Cancer. 2024 Nov;25(7):e295-e303.e4. doi: 10.1016/j.cllc.2024.04.017. Epub 2024 Apr 30. PubMed 38879393 ↗
  • Niu R, Zhang Y, Pang J, Zhou Q, Lei Y, Du Y. Effective treatment of advanced lung adenocarcinoma with paraneoplastic leukemoid reaction with Lorlatinib: a case report. Front Oncol. 2024 Jan 26;14:1341233. doi: 10.3389/fonc.2024.1341233. eCollection 2024. PubMed 38344203 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Aug 2020, 15 months.

Results were first posted in Oct 2021, 1 year 2 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 15 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2019
First posted
Apr 10, 2019
StartActual
Apr 28, 2019
Primary completionActual
Aug 10, 2020
CompletionActual
Oct 21, 2024
Results first posted
Oct 26, 2021
Last update
Nov 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03909971
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 10, 2019
Start date
Apr 28, 2019
Primary completion
Aug 10, 2020
Completion
Oct 21, 2024
Results posted
Oct 26, 2021
Last update
Nov 5, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorlatinib

Start the discussion